Comparing Haloperidol and Olanzapine in Treating Terminal Delirium
NCT ID: NCT04750395
Last Updated: 2023-03-01
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE2
Total Enrollment
80 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-09-01
Study Completion Date
2024-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
As patients with terminal illness enter the dying phase, they may experience symptoms of restlessness, agitation, or cognitive disturbance, known as terminal delirium. In community care, pharmacological therapies are utilized to manage the syndrome, the most commonly used being neuroleptics haloperidol and olanzapine.
However, there is currently a dearth of studies on the efficacy and safety between haloperidol and olanzapine in the community palliative care setting; existing studies involve non-terminal patients in the hospital suffering from acute delirium. To fill this gap, an open-label randomized clinical trial is proposed to compare the effects of haloperidol and olanzapine in the management of terminal delirium in home hospice patients who are imminently dying. Key outcome measures are the reduction of delirium symptoms and the reduction of agitation. Secondary outcome is comparing the adverse effect burden on patients.
However, there is currently a dearth of studies on the efficacy and safety between haloperidol and olanzapine in the community palliative care setting; existing studies involve non-terminal patients in the hospital suffering from acute delirium. To fill this gap, an open-label randomized clinical trial is proposed to compare the effects of haloperidol and olanzapine in the management of terminal delirium in home hospice patients who are imminently dying. Key outcome measures are the reduction of delirium symptoms and the reduction of agitation. Secondary outcome is comparing the adverse effect burden on patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial
NCT04833023
Haloperidol
Advanced Cancer
Hyperactive Delirium
+2 more
RECRUITING
PHASE3
Haloperidol vs Olanzapine for the Management of ICU Delirium
NCT00833300
Delirium
Agitation
TERMINATED
NA
Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer
NCT01539733
Delirium
Advanced Cancer
COMPLETED
NA
Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy
NCT05431595
Delirium
Epileptics
Neuroleptics
RECRUITING
PHASE2/PHASE3
IM Olanzapine Versus Haloperidol or Midazolam
NCT02380118
Acute Agitation, Behavioural Emergency
TERMINATED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Our study defines "terminal delirium" as an episode of delirium that occurs during the dying phase, usually 72 hours before death. Episodes of delirium in the dying phase may be described as "terminal restlessness" or "terminal delirium". The use of the label "terminal" implies a causal relationship between the dying phase and the delirium, although the aetiology is often multi-factorial.
A prospective, open-label, randomized controlled trial was designed. When a home hospice clinician identifies a patient who meets inclusion criteria, their proxy (i.e. family caregivers) will be approached by the study team and invited to participate in the study. Patients will be randomly assigned to one of two groups as part of follow-up management: (i) Oral Transmucosal Haloperidol or (ii) Oral Transmucosal Olanzapine.
After commencement of the first dose of medication, each patient will be observed by their family caregiver and the attending clinician over 72 hours (less if the patient dies earlier). Time-points for data collection will be at 24 hours, 48 hours, and 72 hours after first commencement of medication.
This study compares two common treatments in clinical practice, both of which have demonstrated efficacy greater than placebo. Since all participants will receive treatment that is no different from accepted practice, a placebo group was deemed unnecessary and unethical, thus it was not included.
Proxy consent is a method for collecting informed consent, where the proxy (or person responsible) for the potential participant is approached to provide consent on behalf of the prospective participant. Proxy consent was suggested as a suitable method for consent collection, given the patient's absent or fluctuating capacity to consent. It was successfully used in dementia and delirium research, and was reported to have been acceptable to patients and their caregivers.
The clinical staff of the hospice service will be briefed about the study and will assist in recruitment. As they provide standard palliative care to the patient, the clinical staff will (i) identify patients who meet inclusion criteria and share preliminary information with caregivers, (ii) confirm the diagnosis of delirium, and (iii) advise caregivers on appropriate non-pharmacological management.
The primary caregiver (i.e. proxy) will be approached by a study team member who is independent from the management of the patient. They will provide more detailed information about the study to the primary caregiver. If agreeable, the proxy will sign the informed consent form and the dyad is assigned a participant ID number. Basic demographic information, including patient's age, sex, primary diagnosis and co-morbidities will be collected.
Patients may withdraw from the study anytime, without compromising further treatment using other drugs or alternative dosage regimen.
Randomization sequence is created using Microsoft Excel 2016 with 1:1 allocation using random block sizes of 2 and 4. As each participant joins, they are dispensed either haloperidol or olanzapine according to the generated randomization list.
After obtaining consent, the participant-caregiver pair will be randomized into either the Haloperidol or Olanzapine group. Instructions on how to administer the medication will be provided. Caregivers will be advised to serve breakthrough doses of the assigned anti-psychotic drug as needed.
A daily pack of medication will be prepared for the caregiver during daily clinical reviews at home. The pack will have the correct dosages of medication prepared. Subcutaneous (SC) Midazolam is prepared as rescue medication in the event delirium symptoms remain uncontrolled and distressing after the trial medication are depleted.
Per clinical practice, the first dose of medication will be given under the supervision of the study team. The caregiver will be instructed how to rate the patient using the RASS and will provide the baseline RASS rating. The study team will assess the patient's baseline symptom severity with the MDAS.
Alongside drug therapy, usual non-pharmacological interventions will be provided to all patients. These interventions include: (i) regularly orientating the patient, (ii) keeping the room bright during the day, (iii) minimizing the use of tubes, catheters, physical restraints or other immobilizing devices, and (iv) minimizing unnecessary disturbances to the patient.
Every six hours, caregivers will chart the patient's agitation using the RASS. Additionally, if breakthrough medication is required, the time of administration will be documented.
To conduct assessments as well as to ensure patient's safety, the study team will make regular home visits to review the patient 24-hours, 48-hours, and 72-hours after first dose. During each review, the study team will document their assessments of patients' symptom severity (MDAS) and observe for adverse events (NCI CTCAE). The researchers will take appropriate action to ensure patient's safety during the trial, up to and including recommending the termination of the trial.
The trial will be conducted for up to 72 hours after recruitment or until patient's death. If the patient completes the trial and survives, the family will continue to receive support from their primary nurse and attending physician. Patients who survive beyond seven days after recruitment will be excluded from per-protocol analysis, as they no longer fit the inclusion criteria for the study.
The study may be terminated at any point during the trial. In that event, the caregivers will cease assessment using the RASS, while the clinicians will record the reason for cessation, and make a final MDAS and NCI CTC assessment, where applicable. The family will continue to receive support from their primary nurse and attending physician.
The proxy may choose to decline from having the patient participate in the trial. They may also choose to withdraw the patient from the study at any point during the trial. The patient and the family will continue to receive service support from their primary nurse and attending physician thereafter. They will advise how persisting symptoms should be managed, outside of the study. The study team will assure the proxy of this fact before informed consent is collected.
SC Midazolam is prepared as rescue medication in the event the symptoms of delirium remain uncontrolled and distressing. Rescue medications will be used in any one of the following situations:
1. Within 24 hours, the total doses for Haloperidol or Olanzapine reach more than 10mg or 20mg respectively and patient remains unsettled (i.e. all prepared medication are finished any time before the next clinical review).
2. Patient is unable to tolerate Oral Transmucosal medication.
3. Patient experiences serious adverse effects from trial medication.
The study will be terminated for that patient in any one of the following situations:
1. Rescue medication is used.
2. Adverse events related to the trial medication were observed to be intolerable.
3. Caregiver asks to withdraw the patient from the study.
4. Patient is admitted to hospital.
Changes to the severity of delirium are analysed with scores from MDAS. Repeated-measures, between-factors ANOVA will be employed to analyse differences in MDAS scores over time.
If a statistically significant difference is found between medications, post-hoc analysis will be conducted to analyse the change in MDAS scores at each time-point.
Changes in the patient's agitation will be trended using the RASS score. The RASS scores from Baseline, 6 hours, 12 hours, and 24 hours will be analysed. Moreover, an average of the RASS scores for the second day and the third day will be calculated and trended.
Secondary outcomes are possible adverse effects due to the medication, which is measured using NCI CTCAE. For each group, the toxicities (Akathasia, Extrapyramidal disorder, and spasticity) for each group will be compared.
Based on validation studies by Breitbart et al. (1997) and Lawlor et al. (2000), the mean MDAS scores for patients with delirium is roughly 18 (SD = 7.64). Jain et al. (2018) reported that using either Haloperidol or Olanzapine led to nearly 55% reduction in patients' MDAS score (7-8 points). 2 points was estimated to be the minimal important difference between Haloperidol and Olanzapine.
Assuming a data collection period of 27 months and a target recruitment size of 80 participants, the study must successfully recruit 3 - 4 participants per month.
A review of HCA Hospice Care's medical notes from January 2020 to August 2020 found that 250 patients exhibited symptoms of confusion, agitation, or delirium while in an unstable or deteriorating state (approximately 30 patients per month). The duration between the date of these case notes and the date of patient's death ranged 0 days to 17 days; 187 patients died within 7 days. Hence, an average of 23 potential patients per month would be recruited for the study.
A prospective, open-label, randomized controlled trial was designed. When a home hospice clinician identifies a patient who meets inclusion criteria, their proxy (i.e. family caregivers) will be approached by the study team and invited to participate in the study. Patients will be randomly assigned to one of two groups as part of follow-up management: (i) Oral Transmucosal Haloperidol or (ii) Oral Transmucosal Olanzapine.
After commencement of the first dose of medication, each patient will be observed by their family caregiver and the attending clinician over 72 hours (less if the patient dies earlier). Time-points for data collection will be at 24 hours, 48 hours, and 72 hours after first commencement of medication.
This study compares two common treatments in clinical practice, both of which have demonstrated efficacy greater than placebo. Since all participants will receive treatment that is no different from accepted practice, a placebo group was deemed unnecessary and unethical, thus it was not included.
Proxy consent is a method for collecting informed consent, where the proxy (or person responsible) for the potential participant is approached to provide consent on behalf of the prospective participant. Proxy consent was suggested as a suitable method for consent collection, given the patient's absent or fluctuating capacity to consent. It was successfully used in dementia and delirium research, and was reported to have been acceptable to patients and their caregivers.
The clinical staff of the hospice service will be briefed about the study and will assist in recruitment. As they provide standard palliative care to the patient, the clinical staff will (i) identify patients who meet inclusion criteria and share preliminary information with caregivers, (ii) confirm the diagnosis of delirium, and (iii) advise caregivers on appropriate non-pharmacological management.
The primary caregiver (i.e. proxy) will be approached by a study team member who is independent from the management of the patient. They will provide more detailed information about the study to the primary caregiver. If agreeable, the proxy will sign the informed consent form and the dyad is assigned a participant ID number. Basic demographic information, including patient's age, sex, primary diagnosis and co-morbidities will be collected.
Patients may withdraw from the study anytime, without compromising further treatment using other drugs or alternative dosage regimen.
Randomization sequence is created using Microsoft Excel 2016 with 1:1 allocation using random block sizes of 2 and 4. As each participant joins, they are dispensed either haloperidol or olanzapine according to the generated randomization list.
After obtaining consent, the participant-caregiver pair will be randomized into either the Haloperidol or Olanzapine group. Instructions on how to administer the medication will be provided. Caregivers will be advised to serve breakthrough doses of the assigned anti-psychotic drug as needed.
A daily pack of medication will be prepared for the caregiver during daily clinical reviews at home. The pack will have the correct dosages of medication prepared. Subcutaneous (SC) Midazolam is prepared as rescue medication in the event delirium symptoms remain uncontrolled and distressing after the trial medication are depleted.
Per clinical practice, the first dose of medication will be given under the supervision of the study team. The caregiver will be instructed how to rate the patient using the RASS and will provide the baseline RASS rating. The study team will assess the patient's baseline symptom severity with the MDAS.
Alongside drug therapy, usual non-pharmacological interventions will be provided to all patients. These interventions include: (i) regularly orientating the patient, (ii) keeping the room bright during the day, (iii) minimizing the use of tubes, catheters, physical restraints or other immobilizing devices, and (iv) minimizing unnecessary disturbances to the patient.
Every six hours, caregivers will chart the patient's agitation using the RASS. Additionally, if breakthrough medication is required, the time of administration will be documented.
To conduct assessments as well as to ensure patient's safety, the study team will make regular home visits to review the patient 24-hours, 48-hours, and 72-hours after first dose. During each review, the study team will document their assessments of patients' symptom severity (MDAS) and observe for adverse events (NCI CTCAE). The researchers will take appropriate action to ensure patient's safety during the trial, up to and including recommending the termination of the trial.
The trial will be conducted for up to 72 hours after recruitment or until patient's death. If the patient completes the trial and survives, the family will continue to receive support from their primary nurse and attending physician. Patients who survive beyond seven days after recruitment will be excluded from per-protocol analysis, as they no longer fit the inclusion criteria for the study.
The study may be terminated at any point during the trial. In that event, the caregivers will cease assessment using the RASS, while the clinicians will record the reason for cessation, and make a final MDAS and NCI CTC assessment, where applicable. The family will continue to receive support from their primary nurse and attending physician.
The proxy may choose to decline from having the patient participate in the trial. They may also choose to withdraw the patient from the study at any point during the trial. The patient and the family will continue to receive service support from their primary nurse and attending physician thereafter. They will advise how persisting symptoms should be managed, outside of the study. The study team will assure the proxy of this fact before informed consent is collected.
SC Midazolam is prepared as rescue medication in the event the symptoms of delirium remain uncontrolled and distressing. Rescue medications will be used in any one of the following situations:
1. Within 24 hours, the total doses for Haloperidol or Olanzapine reach more than 10mg or 20mg respectively and patient remains unsettled (i.e. all prepared medication are finished any time before the next clinical review).
2. Patient is unable to tolerate Oral Transmucosal medication.
3. Patient experiences serious adverse effects from trial medication.
The study will be terminated for that patient in any one of the following situations:
1. Rescue medication is used.
2. Adverse events related to the trial medication were observed to be intolerable.
3. Caregiver asks to withdraw the patient from the study.
4. Patient is admitted to hospital.
Changes to the severity of delirium are analysed with scores from MDAS. Repeated-measures, between-factors ANOVA will be employed to analyse differences in MDAS scores over time.
If a statistically significant difference is found between medications, post-hoc analysis will be conducted to analyse the change in MDAS scores at each time-point.
Changes in the patient's agitation will be trended using the RASS score. The RASS scores from Baseline, 6 hours, 12 hours, and 24 hours will be analysed. Moreover, an average of the RASS scores for the second day and the third day will be calculated and trended.
Secondary outcomes are possible adverse effects due to the medication, which is measured using NCI CTCAE. For each group, the toxicities (Akathasia, Extrapyramidal disorder, and spasticity) for each group will be compared.
Based on validation studies by Breitbart et al. (1997) and Lawlor et al. (2000), the mean MDAS scores for patients with delirium is roughly 18 (SD = 7.64). Jain et al. (2018) reported that using either Haloperidol or Olanzapine led to nearly 55% reduction in patients' MDAS score (7-8 points). 2 points was estimated to be the minimal important difference between Haloperidol and Olanzapine.
Assuming a data collection period of 27 months and a target recruitment size of 80 participants, the study must successfully recruit 3 - 4 participants per month.
A review of HCA Hospice Care's medical notes from January 2020 to August 2020 found that 250 patients exhibited symptoms of confusion, agitation, or delirium while in an unstable or deteriorating state (approximately 30 patients per month). The duration between the date of these case notes and the date of patient's death ranged 0 days to 17 days; 187 patients died within 7 days. Hence, an average of 23 potential patients per month would be recruited for the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Delirium
Terminal Illness
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
This is a prospective, open-label, randomized controlled trial. Patients will be randomly assigned to one of two groups as part of follow-up management.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Haloperidol
Every 24 hours, patients will receive two regular doses of OT Haloperidol 2.5mg. Patients may also receive up to two breakthrough doses within a minimum interval of one hour from the last dose. In total, up to four doses of medication will be prepared.
Group Type
EXPERIMENTAL
Haloperidol Solution
Intervention Type
DRUG
Oral transmucosal haloperidol solution 2.5mg
Olanzapine
Every 24 hours, patients will receive two regular doses of OT Olanzapine 5.0mg. Patients may also receive up to two breakthrough doses within a minimum interval of one hour from the last dose. In total, up to four doses of medication will be prepared.
Group Type
EXPERIMENTAL
Olanzapine Tablets
Intervention Type
DRUG
Oral transmucosal olanzapine tablet 5.0mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Haloperidol Solution
Oral transmucosal haloperidol solution 2.5mg
Intervention Type
DRUG
Olanzapine Tablets
Oral transmucosal olanzapine tablet 5.0mg
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Patient is above 21 years of age.
2. Patient was diagnosed with a terminal illness and is receiving end-of-life care at home.
3. Patient is assessed to be acutely dying (estimated prognosis of three days or less).
4. Patient is diagnosed with delirium, as described in the DSM-V (American Psychiatric Association, 2013)
2. Patient was diagnosed with a terminal illness and is receiving end-of-life care at home.
3. Patient is assessed to be acutely dying (estimated prognosis of three days or less).
4. Patient is diagnosed with delirium, as described in the DSM-V (American Psychiatric Association, 2013)
Exclusion Criteria
1. Patient does not have a caregiver at home.
2. Patient has a prior history of dementia, psychosis, schizophrenia or any other mental health issue followed up by psychiatrists or other specialists.
3. Patient is currently receiving, or has been administered Haloperidol or Olanzapine less than a week before participating in the study.
4. Patient has known allergies or adverse reactions to Haloperidol or Olanzapine.
5. Patients who survive 7 days after recruitment will be excluded from the study.
2. Patient has a prior history of dementia, psychosis, schizophrenia or any other mental health issue followed up by psychiatrists or other specialists.
3. Patient is currently receiving, or has been administered Haloperidol or Olanzapine less than a week before participating in the study.
4. Patient has known allergies or adverse reactions to Haloperidol or Olanzapine.
5. Patients who survive 7 days after recruitment will be excluded from the study.
Minimum Eligible Age
21 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HCA Hospice Care
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Poh Heng Chong, MD
Role: STUDY_DIRECTOR
HCA Hospice Care
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HCA Hospice Care
Singapore, , Singapore
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Singapore
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Agar M, Ko DN, Sheehan C, Chapman M, Currow DC. Informed consent in palliative care clinical trials: challenging but possible. J Palliat Med. 2013 May;16(5):485-91. doi: 10.1089/jpm.2012.0422. Epub 2013 Apr 30.
Reference Type
BACKGROUND
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders: DSM-V (5th ed.). Arlington: American Psychiatric Association.
Reference Type
BACKGROUND
Bannon L, McGaughey J, Verghis R, Clarke M, McAuley DF, Blackwood B. The effectiveness of non-pharmacological interventions in reducing the incidence and duration of delirium in critically ill patients: a systematic review and meta-analysis. Intensive Care Med. 2019 Jan;45(1):1-12. doi: 10.1007/s00134-018-5452-x. Epub 2018 Nov 30.
Reference Type
BACKGROUND
Breitbart W, Rosenfeld B, Roth A, Smith MJ, Cohen K, Passik S. The Memorial Delirium Assessment Scale. J Pain Symptom Manage. 1997 Mar;13(3):128-37. doi: 10.1016/s0885-3924(96)00316-8.
Reference Type
BACKGROUND
Bush SH, Grassau PA, Yarmo MN, Zhang T, Zinkie SJ, Pereira JL. The Richmond Agitation-Sedation Scale modified for palliative care inpatients (RASS-PAL): a pilot study exploring validity and feasibility in clinical practice. BMC Palliat Care. 2014 Mar 31;13(1):17. doi: 10.1186/1472-684X-13-17.
Reference Type
BACKGROUND
Bush SH, Kanji S, Pereira JL, Davis DHJ, Currow DC, Meagher D, Rabheru K, Wright D, Bruera E, Hartwick M, Gagnon PR, Gagnon B, Breitbart W, Regnier L, Lawlor PG. Treating an established episode of delirium in palliative care: expert opinion and review of the current evidence base with recommendations for future development. J Pain Symptom Manage. 2014 Aug;48(2):231-248. doi: 10.1016/j.jpainsymman.2013.07.018. Epub 2014 Jan 28.
Reference Type
BACKGROUND
Bush SH, Leonard MM, Agar M, Spiller JA, Hosie A, Wright DK, Meagher DJ, Currow DC, Bruera E, Lawlor PG. End-of-life delirium: issues regarding recognition, optimal management, and the role of sedation in the dying phase. J Pain Symptom Manage. 2014 Aug;48(2):215-30. doi: 10.1016/j.jpainsymman.2014.05.009. Epub 2014 May 28.
Reference Type
BACKGROUND
Casarett DJ, Inouye SK; American College of Physicians-American Society of Internal Medicine End-of-Life Care Consensus Panel. Diagnosis and management of delirium near the end of life. Ann Intern Med. 2001 Jul 3;135(1):32-40. doi: 10.7326/0003-4819-135-1-200107030-00011.
Reference Type
BACKGROUND
Finucane AM, Jones L, Leurent B, Sampson EL, Stone P, Tookman A, Candy B. Drug therapy for delirium in terminally ill adults. Cochrane Database Syst Rev. 2020 Jan 21;1(1):CD004770. doi: 10.1002/14651858.CD004770.pub3.
Reference Type
BACKGROUND
Gagnon P, Allard P, Gagnon B, Merette C, Tardif F. Delirium prevention in terminal cancer: assessment of a multicomponent intervention. Psychooncology. 2012 Feb;21(2):187-94. doi: 10.1002/pon.1881. Epub 2010 Dec 19.
Reference Type
BACKGROUND
Hui D, Dev R, Bruera E. Neuroleptics in the management of delirium in patients with advanced cancer. Curr Opin Support Palliat Care. 2016 Dec;10(4):316-323. doi: 10.1097/SPC.0000000000000236.
Reference Type
BACKGROUND
Hui D, Hess K, Dibaj SS, Arthur J, Dev R, Dalal S, Reddy S, Bruera E. The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium. Cancer. 2018 May 15;124(10):2246-2252. doi: 10.1002/cncr.31312. Epub 2018 Feb 22.
Reference Type
BACKGROUND
Kim J, Shin W. How to do random allocation (randomization). Clin Orthop Surg. 2014 Mar;6(1):103-9. doi: 10.4055/cios.2014.6.1.103. Epub 2014 Feb 14.
Reference Type
BACKGROUND
Lawlor PG, Nekolaichuk C, Gagnon B, Mancini IL, Pereira JL, Bruera ED. Clinical utility, factor analysis, and further validation of the memorial delirium assessment scale in patients with advanced cancer: Assessing delirium in advanced cancer. Cancer. 2000 Jun 15;88(12):2859-67.
Reference Type
BACKGROUND
Mercadante S, Masedu F, Maltoni M, De Giovanni D, Montanari L, Pittureri C, Berte R, Russo D, Ursini L, Marinangeli F, Aielli F. Symptom expression in advanced cancer patients admitted to hospice or home care with and without delirium. Intern Emerg Med. 2019 Jun;14(4):515-520. doi: 10.1007/s11739-018-1969-9. Epub 2018 Oct 17.
Reference Type
BACKGROUND
Morita T, Hirai K, Sakaguchi Y, Tsuneto S, Shima Y. Family-perceived distress from delirium-related symptoms of terminally ill cancer patients. Psychosomatics. 2004 Mar-Apr;45(2):107-13. doi: 10.1176/appi.psy.45.2.107.
Reference Type
BACKGROUND
Reston JT, Schoelles KM. In-facility delirium prevention programs as a patient safety strategy: a systematic review. Ann Intern Med. 2013 Mar 5;158(5 Pt 2):375-80. doi: 10.7326/0003-4819-158-5-201303051-00003.
Reference Type
BACKGROUND
Sweet L, Adamis D, Meagher DJ, Davis D, Currow DC, Bush SH, Barnes C, Hartwick M, Agar M, Simon J, Breitbart W, MacDonald N, Lawlor PG. Ethical challenges and solutions regarding delirium studies in palliative care. J Pain Symptom Manage. 2014 Aug;48(2):259-71. doi: 10.1016/j.jpainsymman.2013.07.017. Epub 2013 Dec 31.
Reference Type
BACKGROUND
Jain R, Arun P, Sidana A, Sachdev A. Comparison of efficacy of haloperidol and olanzapine in the treatment of delirium. Indian J Psychiatry. 2017 Oct-Dec;59(4):451-456. doi: 10.4103/psychiatry.IndianJPsychiatry_59_17.
Reference Type
RESULT
Lyu XJ, Kan AD, Chong PH, Lin K, Koh YH, Yeo ZZ. An open-label clinical trial of oral transmucosal haloperidol and oral transmucosal olanzapine in the treatment of terminal delirium at home. Trials. 2022 Apr 14;23(1):311. doi: 10.1186/s13063-022-06238-4.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21-HALOLAN
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia
NCT00485901
COMPLETED
PHASE3
To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00007774
COMPLETED
PHASE4
Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation
NCT03211897
COMPLETED
Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer
NCT00124930
TERMINATED
PHASE3
Optimisation of Antipsychotic Drug Use in Older People
NCT01454453
TERMINATED
PHASE4
A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia
NCT00044044
COMPLETED
PHASE2
Oral Olanzapine Versus Haloperidol or Diazepam
NCT03246620
TERMINATED
PHASE4
Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia
NCT00797277
COMPLETED
PHASE3
A Study of Olanzapine in Patients With Acute Agitation
NCT05803642
UNKNOWN
PHASE3
Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00001656
COMPLETED
PHASE4
Amisulpride Treatment for BPSD in AD Patients
NCT04341467
UNKNOWN
NA
Clozapine and Olanzapine Treatment of Aggression
NCT01123408
COMPLETED
NA
Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa
NCT00692185
COMPLETED
PHASE2
Treating Drug-Resistant Childhood Schizophrenia
NCT00048828
COMPLETED
PHASE4
Olanzapine in the Treatment of Hair Pulling (Trichotillomania)
NCT00182507
COMPLETED
PHASE4
"Extended" (Alternate Day) Antipsychotic Dosing
NCT04478838
RECRUITING
PHASE4
Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)
NCT00693472
TERMINATED
PHASE2
Prophylactic Olanzapine Versus Placebo for Prevention of Postoperative Delirium After Joint Replacement Surgery
NCT00699946
COMPLETED
NA
Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride
NCT00632645
COMPLETED
PHASE3
Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)
NCT00156117
COMPLETED
PHASE3
Long-acting Paliperidone Palmitate Injection and Olanzapine for Schizophrenia
NCT02918825
COMPLETED
NA
Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00100776
COMPLETED
PHASE4
To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal Volunteers
NCT00946491
COMPLETED
PHASE1
A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia
NCT00640510
COMPLETED
PHASE3
Antipsychotic Polypharmacy in Schizophrenia
NCT00493233
COMPLETED
NA